Virtu Financial’s Rubius Therapeutics, Inc RUBY Stock Holding History

Virtu Financial’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-68,825	Closed	-$12K	–	2440
2022 Q4	$12K	Buy	68,825 +41,338	+150%	+$11.3K	﹤0.01%	1366
2022 Q3	$12K	Buy	+27,487	New	+$20.6K	﹤0.01%	1501
2021 Q2	–	Sell	-20,334	Closed	-$539K	–	2269
2021 Q1	$539K	Buy	+20,334	New	+$297K	0.04%	486
2019 Q4	$106K	Buy	+11,190	New	+$108K	0.01%	1072

Other funds holding RUBY

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

CGL

Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Virtu Financial's RUBY Position: Q1 2023 in Review

Virtu Financial sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 68,825 shares — an estimated $12K sold.

Virtu Financial first reported a position in RUBY in Q4 2019 and held it in 4 quarters. The position peaked at $539K in Q1 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

Virtu Financial reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
Virtu Financial sold 68,825 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $12K.
Virtu Financial first reported a position in Rubius Therapeutics, Inc in Q4 2019 and held it in 4 quarters.
Virtu Financial's Rubius Therapeutics, Inc position peaked at $539K in Q1 2021.
7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Virtu Financial's 13F filing for Q1 2023, filed 1 May 2023.